BioCardia, Inc. (BCDA)
Largest Insider Buys in Sector
BCDA Stock Price History Chart
BCDA Stock Performance
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the …
Insider Activity of BioCardia, Inc.
Over the last 12 months, insiders at BioCardia, Inc. have bought $0 and sold $55,815 worth of BioCardia, Inc. stock.
On average, over the past 5 years, insiders at BioCardia, Inc. have bought $660,900 and sold $55,815 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,000 shares for transaction amount of $3,484 was made by Altman Peter (President and CEO) on 2023‑08‑17.
List of Insider Buy and Sell Transactions, BioCardia, Inc.
| 2024-01-19 | Sale | 10 percent owner | 129,802 0.5902% | $0.43 | $55,815 | -19.97% | ||
| 2023-08-17 | President and CEO | 4,000 0.0199% | $0.87 | $3,484 | -52.24% | |||
| 2023-08-14 | President and CEO | 4,500 0.022% | $0.88 | $3,978 | -53.88% | |||
| 2023-05-26 | President and CEO | 6,200 0.0264% | $1.60 | $9,920 | -75.30% | |||
| 2022-12-16 | director | 595,238 3.3% | $1.68 | $1,000,000 | +9.94% | |||
| 2022-11-11 | President and CEO | 1,400 0.0079% | $1.86 | $2,604 | +1.89% | |||
| 2022-11-10 | President and CEO | 3,100 0.0176% | $1.87 | $5,797 | +1.08% | |||
| 2022-10-10 | Chief Financial Officer | 2,000 0.0112% | $2.07 | $4,140 | -4.75% | |||
| 2022-09-23 | President and CEO | 1,400 0.0079% | $1.87 | $2,618 | +6.99% | |||
| 2022-09-22 | President and CEO | 3,100 0.017% | $1.81 | $5,611 | +7.57% | |||
| 2022-09-21 | President and CEO | 2,750 0.0163% | $1.92 | $5,280 | +9.34% | |||
| 2022-01-11 | President and CEO | 100 0.0006% | $1.87 | $187 | -2.14% | |||
| 2020-06-19 | director | 142,850 1.6989% | $2.10 | $299,985 | +44.98% | |||
| 2020-06-19 | director, 10 percent owner | 142,850 1.6989% | $2.10 | $299,985 | +44.98% | |||
| 2020-06-19 | director | 142,850 1.6989% | $2.10 | $299,985 | +44.98% | |||
| 2020-03-24 | President and CEO | 1,200 0.0185% | $2.90 | $3,480 | +3.09% | |||
| 2020-03-19 | President and CEO | 400 0.0058% | $2.95 | $1,180 | -6.52% | |||
| 2020-03-18 | President and CEO | 3,300 0.0555% | $2.53 | $8,349 | +27.05% | |||
| 2020-03-17 | President and CEO | 200 0.0037% | $3.66 | $732 | -4.64% | |||
| 2020-03-12 | President and CEO | 3,400 0.0413% | $3.15 | $10,710 | -26.97% |
Insider Historical Profitability
| FROST PHILLIP MD ET AL | 10 percent owner | 1896025 54.1432% | $2.41 | 19 | 2 | +9.94% |
| Brooks Andrew A | CEO | 63560031 1815.0312% | $2.41 | 11 | 0 | |
| BROOKS JONATHAN | director, 10 percent owner | 32045292 915.0909% | $2.41 | 1 | 2 | |
| Allen Jim L. | director | 668200 19.0812% | $2.41 | 1 | 0 | +44.98% |
| Altman Peter | President and CEO | 447339 12.7743% | $2.41 | 61 | 0 | <0.0001% |